



East London
NHS Foundation Trust

Information Governance

The Green
1 Roger Dowley Court
Russia Lane
London
E2 9NJ

Email elft.foi@nhs.net

Website: <https://www.elft.nhs.uk>

7th April 2022

Our reference: FOI DA4162

I am responding to your request for information received **1st April**. This has been treated as a request under the Freedom of Information Act 2000.

I am now enclosing a response which is attached to the end of this letter. Please do not hesitate to contact me on the contact details above if you have any further queries.

Yours sincerely,

Lara Cousens
Information Governance Manager – Information Rights

If you are dissatisfied with the Trust's response to your FOIA request then you should contact us and we will arrange for an internal review of this decision.

If you remain dissatisfied with the decision following our response to your complaint, you may write to the Information Commissioner for a decision under Section 50 of the Freedom of Information Act 2000. The Information Commissioner can be contacted at:

Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Tel: 0303 123 1113
Web: www.ico.org.uk

Please note that the data supplied is not allowed to be re-used and/or published without the explicit consent of East London NHS Foundation Trust. Please contact the signatory to request permission if this is your intention

Chair: Eileen Taylor (Interim)

Chief Executive: Paul Calaminus

We care

We respect

We are inclusive

Request:

Question 1: In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

- **Bevacizumab (Avastin)**
- **Dacarbazine (DTIC)**
- **Trametinib (Mekinist)**
- **Dabrafenib (Tafinlar)**
- **Ipilimumab (Yervoy)**
- **Vemurafenib (Zelboraf)**
- **Nivolumab (Opdivo)**
- **Nivolumab + Ipilimumab (Opdivo + Yervoy)**
- **Pembrolizumab (Keytruda)**
- **Vemurafenib + cobimetinib (Zelboraf + Cotellic)**
- **Dabrafenib + Trametinib (Tafinlar + Mekinist)**
- **Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients**
- **Other active systemic anti-cancer therapy [please state]**
- **Palliative care only**

Question 2: In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

- **Ipilimumab**
- **Ipilimumab AND Nivolumab**
- **Nivolumab**
- **Pembrolizumab**
- **Dabrafenib AND Trametinib**
- **Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)**
- **Other active systemic anti-cancer therapy**
- **Palliative care only**

Answer: Section 1(1) of the Freedom of Information Act 2000 states:

Any person making a request for information to a public authority is entitled—

- (a) to be informed in writing by the public authority whether it holds information of the description specified in the request, and
- (b) if that is the case, to have that information communicated to him.

East London NHS Foundation Trust is a mental and community health trust and does not provide treatment in relation to the above questions 1 – 2. Therefore the Trust is unable to disclose this information.

Chair: Eileen Taylor (Interim)

Chief Executive: Paul Calaminus

We care

We respect

We are inclusive